metsera glp-1 Unveils Promising Phase 1 Data on Receptor Agonist for Weight Loss Pfizer's Metsera GLP-1 hits mark

Weight loss may play a role for liver health in patients, but with Ehlers-Danlos Syndrome (EDS) and MCAS, liver disease is not uncommon even when very slender

There are currently studies testing an oral form of semaglutide for weight management that is a higher dose and will likely be FDA approved in the future for obesity

Heart rate effects peak around week 24 of treatment and then decline at weeks 36 and 48 even with continued dosing

Popular weight-loss drugs known as GLP-1s could soon become more affordable for Americans

I needed some encouragement to loose some weight for health reasons and this group have been very supportive to my cause

One reason these drugs are so effective in treating obesity could be that they address the underlying addiction